Whitaker I S, Rao J, Izadi D, Butler P E
Department of Anatomy, University of Cambridge, Cambridge, UK.
Br J Oral Maxillofac Surg. 2004 Apr;42(2):133-7. doi: 10.1016/S0266-4356(03)00242-0.
Blood letting and the therapeutic use of Hirudo medicinalis date back to ancient Egypt and the beginning of civilisation. Their popularity has varied over the years, reaching such a peak in Europe between 1825 and 1850 that supplies were exhausted. Towards the end of the century they fell out of favour and, during this period, the leech, once used by the physicians of emperors and influential academic surgeons, became associated with lay therapists and quackery. Leeches have enjoyed a renaissance in reconstructive microsurgery during the last 15 years, having been used by maxillofacial [Br. J. Oral Maxillofac. Surg 41 (2003) 44] and other reconstructive surgeons to aid salvage of compromised microvascular free tissue transfers [Laryngoscope 108 (1998) 1129; Br. J. Plast. Surg. 34 (1984) 358], replanted digits [Int. J. Microsurg. 3 (1981) 265], ears [Ann. Plast. Surg. 43 (1999) 427], lips [Plast. Reconstr. Surg. 102 (1998) 358; J. Reconstr. Microsurg. 9 (1993) 327] and nasal tips [Br. J. Oral Maxillofac. Surg. 36 (1998) 462]. Peer-reviewed evidence suggests that the survival of compromised, venous-congested tissues is improved by early application of a leech [J. Reconstr. Microsurg. 12 (1996) 165; Arch. Otolaryngol. Head Neck Surg. 114 (1988) 1395; Br. J. Plast. Surg. 45 (1992) 235]. Leeches have also recently been used to treat a wide range of conditions, including periorbital haematomas [Br. J. Ophthalmol. 75 (1991) 755], severe macroglossia [Otolaryngol. Head Neck Surg. 125 (2001) 649; J. Laryngol. Otol. 109 (1995) 442] and purpura fulminans [Ann. Plast. Surg. 35 (1995) 300]. The first medicinal leech farm, Biopharm, was set up in Swansea in 1981 by Dr Roy Sawyer, and now supplies leeches to hospitals all over the world. In this paper, we summarise the history of treatment with Hirudo medicinalis from its origin to the present day, and take a brief look at the possible future of the annelid.
放血疗法以及医用水蛭的治疗用途可追溯到古埃及和文明之初。多年来,它们的受欢迎程度有所波动,在1825年至1850年间在欧洲达到顶峰,以至于供应耗尽。到世纪末,它们失宠了,在此期间,曾经被皇帝的御医和有影响力的学术外科医生使用的水蛭,与非专业治疗师和江湖医术联系在了一起。在过去15年里,水蛭在重建显微外科中再度受到青睐,颌面外科医生[《英国口腔颌面外科杂志》41 (2003) 44]和其他重建外科医生已使用水蛭来辅助挽救受损的微血管游离组织移植[《喉镜》108 (1998) 1129;《英国整形外科学杂志》34 (1984) 358]、再植手指[《国际显微外科学杂志》3 (1981) 265]、耳朵[《整形外科学年鉴》43 (1999) 427]、嘴唇[《整形与重建外科》102 (1998) 358;《重建显微外科学杂志》9 (1993) 327]和鼻尖[《英国口腔颌面外科杂志》36 (1998) 462]。经同行评审的证据表明,早期应用水蛭可提高受损的静脉充血组织的存活率[《重建显微外科学杂志》12 (1996) 165;《耳鼻咽喉 - 头颈外科档案》114 (1988) 1395;《英国整形外科学杂志》45 (1992) 235]。水蛭最近还被用于治疗多种病症,包括眶周血肿[《英国眼科杂志》75 (1991) 755]、严重巨舌症[《耳鼻咽喉 - 头颈外科》125 (2001) 649;《喉科学与耳科学杂志》109 (1995) 442]和暴发性紫癜[《整形外科学年鉴》35 (1995) 300]。1981年,罗伊·索耶博士在斯旺西建立了第一家医用水蛭养殖场——生物制药公司,如今该公司向世界各地的医院供应水蛭。在本文中,我们总结了医用水蛭从起源到现在的治疗历史,并简要展望了这种环节动物可能的未来。